Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders (2023)

Grace Blest-Hopley, Ben Amit, Aisling O'Neill, & Simon Ruffell

Cannabis and Psilocybin Mushrooms

Medical cannabis and psychedelics have shown promising results in treating various psychiatric disorders, but the lack of robust evidence remains a significant challenge. In this edition, we share intriguing insights into the specific applications of certain substances.

Previous
Previous

Ayahuasca – a review of historical, pharmacological, and therapeutic aspects (2023)

Next
Next

Ayahuasca (in Psychedelics as Psychiatric Medications, 2023)